Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular.
Topics include: how cancer vaccines differ from other vaccines, how AI is driving the creation of new therapeutic cancer vaccines, how cancers evade the immune response, and TG4050, the newest drug candidate Transgene presented recently at ASCO.
